These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9476918)

  • 1. Alpha particle therapy poised to become new line of cancer treatment.
    Kotz D
    J Nucl Med; 1998 Feb; 39(2):17N-19N, 36N. PubMed ID: 9476918
    [No Abstract]   [Full Text] [Related]  

  • 2. The promise of targeted {alpha}-particle therapy.
    Mulford DA; Scheinberg DA; Jurcic JG
    J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.
    Zalutsky MR
    J Nucl Med; 2006 Aug; 47(8):1238-40. PubMed ID: 16882999
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential and pitfalls of therapy with alpha-particles.
    Welch MJ
    J Nucl Med; 2005 Aug; 46(8):1254-5. PubMed ID: 16085579
    [No Abstract]   [Full Text] [Related]  

  • 6. [Alpha-radioimmunotherapy: a review of recent developments].
    Supiot S; Thillays F; Rio E; Mahé MA; Barbet FJ; Kraeber-Bodéré F; Chérel M
    Cancer Radiother; 2007 Sep; 11(5):252-9. PubMed ID: 17604673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can α-radioimmunotherapy increase efficacy for the systemic control of cancer?
    Allen BJ
    Immunotherapy; 2011 Apr; 3(4):455-8. PubMed ID: 21463184
    [No Abstract]   [Full Text] [Related]  

  • 8. Current status and perspectives in alpha radioimmunotherapy.
    Chérel M; Davodeau F; Kraeber-Bodéré F; Chatal JF
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):322-9. PubMed ID: 17043629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
    Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity].
    Ménager J; Gorin JB; Fichou N; Gouard S; Morgenstern A; Bruchertseifer F; Davodeau F; Kraeber-Bodéré F; Chérel M; Gaschet J; Guilloux Y
    Med Sci (Paris); 2016 Apr; 32(4):362-9. PubMed ID: 27137693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
    Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitter?
    Barbet J; Chatal JF
    Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):271-3. PubMed ID: 21161707
    [No Abstract]   [Full Text] [Related]  

  • 13. Alpha particles more promising than toxins?
    Barbet J; Chérel M; Chatal JF
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):849-50. PubMed ID: 20306031
    [No Abstract]   [Full Text] [Related]  

  • 14. Alpha-particles for targeted therapy.
    Sgouros G
    Adv Drug Deliv Rev; 2008 Sep; 60(12):1402-6. PubMed ID: 18541332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.
    Pozzi OR; Zalutsky MR
    J Nucl Med; 2005 Aug; 46(8):1393-400. PubMed ID: 16085599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The average number of alpha-particle hits to the cell nucleus required to eradicate a tumour cell population.
    Roeske JC; Stinchcomb TG
    Phys Med Biol; 2006 May; 51(9):N179-86. PubMed ID: 16625028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
    J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-Particle emitters in radioimmunotherapy: new and welcome challenges to medical internal dosimetry.
    Bolch WE
    J Nucl Med; 2001 Aug; 42(8):1222-4. PubMed ID: 11483683
    [No Abstract]   [Full Text] [Related]  

  • 19. Ac-225 and her daughters: the many faces of Shiva.
    McDevitt MR; Scheinberg DA
    Cell Death Differ; 2002 Jun; 9(6):593-4. PubMed ID: 12032666
    [No Abstract]   [Full Text] [Related]  

  • 20. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
    Akabani G; Kennel SJ; Zalutsky MR
    J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.